“香港HPV疫苗第一股”瑞科生物(2179.HK)首日上市逆勢收漲1.81%
格隆匯3月31日丨大市整體下跌之際,瑞科生物(2179.HK)今日首日上市逆勢收漲1.81%報25.25港元,市值121億港元。此次IPO,揚子江藥業集團、嘉實國際和紅杉中國作為公司的基石投資人,基石認購比例超過50%。此前,公司曾獲君聯資本、LYFE Capital、東方富海、沃盈資本、紅杉中國、清池資本、淡馬錫等眾多知名投資機構的青睞。此次成功在港上市,成為“香港HPV疫苗第一股”、“香港新型佐劑疫苗第一股”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.